Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aytu BioPharma's change in inventory for the quarter that ended in Mar. 2026 was $0.54 Mil. It means Aytu BioPharma's inventory
declined by $0.54 Mil
from Dec. 2025 to Mar. 2026 .
Aytu BioPharma's change in inventory for the fiscal year that ended in Jun. 2025 was $0.38 Mil. It means Aytu BioPharma's inventory
declined by $0.38 Mil
from Jun. 2024 to Jun. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aytu BioPharma's Days Inventory for the quarter that ended in Mar. 2026 was 152.80.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Aytu BioPharma's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.60.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aytu BioPharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.65.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aytu BioPharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aytu BioPharma Change In Inventory Related Terms
Aytu BioPharma Change In Inventory Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $1.69 Mil mean?
Aytu BioPharma (AYTU) has a Change In Inventory of $1.69 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Aytu BioPharma and its competitors.
Is Aytu BioPharma's Change In Inventory too high?
Aytu BioPharma's current Change In Inventory is $1.69 Mil. Overall, Aytu BioPharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Change In Inventory compare to TXMD and MRMD?
Aytu BioPharma's Change In Inventory of $1.69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Aytu BioPharma and its competitors. Aytu BioPharma's current Change In Inventory is $1.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.86, compared to a current price of $2.24 — trading 160.5% above its estimated fair value. The current Change In Inventory is $1.69 Mil. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Change In Inventory is $1.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.24 is trading 160.5% above its estimated GF Value™ of $0.86.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
Change In Inventory: $1.69 Mil
GF Value™: $0.86 vs. price of $2.24 (160.5% above fair value)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
42GF Score
Get the complete analysis for AYTU
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
